The Global Rheumatology Therapeutics Market size was estimated at USD 24568.4 Mn in 2021, growing at a CAGR of 4.2% during the forecast period 2021-2027. Rheumatology is the branch of medicine devoted to diagnosis and treatment of rheumatic diseases. Rheumatology diseases mainly affect the connecting and supporting parts of the body such as ligaments, joints, muscles, tendons and rarely some organs of the body.There are more than 100 types of rheumatic diseases are present but more common are psoriatic arthritis, ankylosing spondylitis, systemic lupus erythematosus, rheumatoid arthritis and others. Rheumatology diseases can be caused by various factors such as change in lifestyle, aging, unhealthy food and even genetic factors. The treatment is generally given with disease modifying anti rheumatic drugs and other drugs may be used to decrease the symptoms. The market is highly competitive due to the presence of the strong market players involving in development of new rheumatology therapeutics. Companies are developing the novel drugs and expanding the therapeutic applications of existing drugs. For instance, in January 2016, Novartis AG has got two U.S. Food and Drug Administration approvals for its County to treat ankylosing spondylitis and psoriatic arthritis in U.S. in May 2017, Sanofi S.A. has got U.S. Food and Drug Administration approval for its kevazara (sarilumab) to treat active rheumatoid arthritis. Furthermore, companies also focusing on inorganic growth through acquisitions and mergers. For instance, in April 2016, Bristol Myers Squib acquired the Padlock Therapeutics Inc. along with the pipeline of rheumatoid arthritis and autoimmune drug pipeline to strengthen their market position.